Biodistribution and blood clearance of plasmid DNA administered in arginine peptide complexes by Woo, Jung Gyu et al.
RESEARCH Open Access
Biodistribution and blood clearance of plasmid
DNA administered in arginine peptide complexes
Jung Gyu Woo, Na Young Kim, Jai Myung Yang and Sungho Shin
*
Abstract
Background: Peptide/DNA complexes have great potential as non-viral methods for gene delivery. Despite
promising results for peptide-mediated gene delivery technology, an effective systemic peptide-based gene
delivery system has not yet been developed.
Methods: This study used pCMV-Luc as a model gene to investigate the biodistribution and the in vivo efficacy of
arginine peptide-mediated gene delivery by polymerase chain reaction (PCR).
Results: Plasmid DNA was detected in all organs tested 1 h after intraperitoneal administration of arginine/DNA
complexes, indicating that the arginine/DNA complexes disseminated widely through the body. The plasmid was
primarily detected in the spleen, kidney, and diaphragm 24 h post administration. The mRNA expression of plasmid
DNA was noted in the spleen, kidney, and diaphragm for up to 2 weeks, and in the other major organs, for at least
1 week. Blood clearance studies showed that injected DNA was found in the blood as long as 6 h after injection.
Conclusions: Taken together, our results demonstrated that arginine/DNA complexes are stable in blood and are
effective for in vivo gene delivery. These findings suggest that intraperitoneal administration of arginine/DNA
complexes is a promising tool in gene therapy.
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Background
Cell-penetrating peptides (CPPs) have been widely shown
to transfer macromolecules into living cells [1,2]. Several
of these peptides have been identified, such as Tat [3],
Antp [4], and VP22 [5]. Carrier peptides, which are fused
to their cargo molecules, provide a method for delivering
intracellularly acting proteins or nucleic acids to cells in
vitro [6,7], ex vivo [8], and in vivo [9,10]. For example, it
was recently reported that CPP sa r eh i g h l ye f f i c i e n ti n
facilitating the cellular uptake of small interfering RNA
(siRNA) [11,12]. Most CPPs contain at least 1 basic amino
acid residue such as arginine or lysine, suggesting that
basic amino acids are critical motifs for the efficient deliv-
ery of exogenous biomolecules into cells [13,14].
The authors have focused on the development of an
arginine peptide-mediated gene delivery system after pre-
viously demonstrating that a short arginine peptide (R15)
is able to condense plasmid DNA into small complexes.
The highest transfection activity in 293T, HeLa, Jurkat,
and COS-7 cells was obtained for arginine/DNA com-
plexes with an N/P ratio of 3:1 [15]. The size of the argi-
nine/DNA complex was shown to be the primary
limitation for transfection efficiency in vitro [16]. Confo-
cal laser fluorescence microscopy data showed that argi-
nine peptides facilitated the movement of DNA from the
cytoplasm, causing DNA to accumulate in the nucleus
[17].
The success of gene therapy depends on the develop-
ment of a vector that achieves efficient, cell-specific, and
prolonged transgene expression after its application [18].
Although viral vectors have the highest transfection effi-
ciency among the many possible gene carriers, safety con-
cerns have led to reconsideration of their use in human
gene therapy. Non-viral vectors such as cationic peptides
are considered safer and easier to prepare than viral vec-
tors, and are, therefore, more attractive vectors for clinical
application of gene therapy [19]. Despite their usefulness,
there has been little systemic in vivo study of peptide vec-
tors. More importantly, studies on the pharmacological
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complexes are completely lacking. Determining critical
pharmacological parameters such as plasmid biodistribu-
tion, blood clearance half-life, in vivo persistence, and gene
expression is very important in the design of new delivery
strategies.
Therefore, the objective of this study was to assess the in
vivo fate of arginine/DNA complexes after their intraperi-
toneal administration in mice using luciferase as a reporter
gene. Organ distribution in terms of plasmid localization,
DNA expression, and circulation kinetics were assessed.
Polymerase chain reaction (PCR) was employed to assess
plasmid DNA and expression of DNA in the different
organs.
Methods
Plasmid DNA
Plasmid DNA containing firefly luciferase under the con-
trol of a CMV-promoter (pCMV-Luc) was provided by
Promega (Madison, WI, USA). The plasmid DNA was
amplified in Escherichia coli TOP10-competent cells and
purified with an AxyPrep™Plasmid Maxiprep Kit (Union
City, CA, USA), according to the manufacturer’si n s t r u c -
tions. The quality of plasmid DNA preparations was deter-
mined using NanoDrop ND-1000 (Wilmington, DE, USA).
Typical optical density (O.D.) at 260/280 nm values were
approximately 1.9. DNA was stored at -20°C until use.
Formation of arginine/DNA complexes
Arginine/DNA complexes were generated at an N/P ratio
of 3:1, as described previously [15]. Plasmid DNA (100 μg)
was added to a 5% glucose solution and 6.1 μLo f1 0m M
arginine peptide (R15; Peptron, Daejeon, Korea) was
added to the final 5% glucose solution and adjusted to a
final volume of 500 μL. To form the arginine/DNA com-
plexes, the solution was pipetted and vigorously mixed by
vortexing. The complex solution was incubated for 15 min
at room temperature (25°C) and intraperitoneally adminis-
tered to the mice.
In vivo gene delivery
All animal work was conducted according to the guide-
lines established by the Institutional Animal Care and Use
Committee of the Sogang University. Female Balb/c mice
(Samtako, Osan, Korea) weighing 19-20 g (5-week-old)
were used for in vivo gene delivery. Five hundred microli-
ters of the arginine/DNA complex (N/P ratio of 3.0;
100 μg pCMV-Luc) in 5% glucose solution was adminis-
tered by intraperitoneal injection with a 27-gauge syringe
needle.
Biodistribution studies
For biodistribution experiments, blood was collected
from the vena cava of Balb/c mice intraperitoneally
injected with the arginine/DNA complex solution under
ether anesthesia at the indicated time points, and the
mice were subsequently killed by cervical dislocation.
The organs (liver, lung, heart, spleen, brain, diaphragm,
and kidney) were removed. Samples were thoroughly
washed with phosphate-buffered saline (PBS) to mini-
mize the influence of plasmid in the blood, blotted dry,
and weighed. Blood samples were treated with heparin
(Sigma, St. Louis, MO, USA) to prevent aggregation.
Isolation of DNA and RNA
At various time points following intraperitoneal adminis-
tration of arginine/DNA complexes, samples of several tis-
sue types were obtained, including the liver, heart, spleen,
brain, diaphragm, kidney, and blood. Subsequently, sam-
ples were homogenized using a BioMasher (Nippi, Tokyo,
Japan) or a glass homogenizer. The DNA was purified
using the DNeasy Blood and Tissue Kit (Qiagen, Valencia,
CA, USA) protocol. Total RNA was extracted from each
sample using the RNeasy Mini Kit (Qiagen).
PCR detection of plasmid DNA
PCR was used to visualize reporter gene biodistribution to
each organ. The primers used in the reactions were as fol-
lows: luciferase forward primer 5’-tgcactgatcatgaactc-3’
and reverse primer 5’-ggacataatcataggacc-3’. The reactions
were set up using 50 ng of total DNA and 2 × Premix Taq
(Takara, Seoul, Korea). The PCR process was controlled
by a MasterCycler (Eppendorf, Hamburg, Germany) as
follows: pre-incubation at 94°C for 5 min, 40 cycles of
denaturation at 94°C for 30 s, annealing at 50°C for 30 s,
extension at 72°C for 40 s, and post-amplification at 72°C
for 7 min. Nested PCR was used to examine blood clear-
ance and the duration of mRNA expression. Reactions
were constructed as an additional nested PCR after the
first PCR. The nested PCR reaction was constructed as fol-
lows: luciferase nested forward 5’-cgctgctggtgccaaccc-3’
and luciferase nested reverse 5’-tttaccgaccgcgcccgg-3’ pri-
mers, template, 3 μL of the first PCR product, and 2 × Pre-
mix Taq. The second PCR thermal cycle was the same as
the first, except that the annealing and extension tempera-
tures and times were 62°C for 30 s and 72°C for 20 s,
respectively. The PCR products were visualized using 1.2%
agarose gel electrophoresis.
Reverse transcription PCR (RT-PCR) assay
To determine the mRNA expression of the administered
plasmid DNA in various organs, mRNA levels were mea-
sured using RT-PCR. To prepare the cDNA templates,
2 μg of total RNA from each organ were used as a tem-
plate for reverse transcription using AccuPower RT Pre-
mix (Bioneer, Daejeon, Korea) with Oligo dT as a primer
for reverse-transcriptase. The cDNA was synthesized at
70°C for 10 min, at 42°C for 1 h, and at 94°C for 5 min.
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The real-time PCR reaction for relative quantification of
luciferase mRNA was performed in 20-μL reaction volume
containing 0.5 μL of luciferase nested forward and reverse
primers, 2 μL template cDNA, 0.4 μL ROX reference dye,
and 10 μL of 2 × SYBR Premix Ex Taq (Takara, Seoul,
Korea). The thermal cycler protocol was set as follows:
pre-incubation at 95°C for 10 s, amplification at 40 cycles
at 95°C for 5 s, and 60°C for 40 s. For the mouse glyceral-
dehyde-3-phosphate dehydrogenase (GAPDH) cDNA
measurements, each sample was prepared following the
manufacturer’s instructions with a GAPDH primer set
(Qiagen). Relative quantification was expressed as the
SYBR fluorescence ratio as luciferase fluorescence/
GAPDH fluorescence.
Results
Biodistribution of intraperitoneally administered plasmid
DNA
The biodistribution of the plasmid DNA was studied
after intraperitoneal administration in mice using PCR
analysis. pCMV-Luc was chosen as a target plasmid.
Mice were injected with arginine/DNA complexes pre-
pared with 100 μg plasmid DNA at an N/P ratio of 3:1
and were sacrificed at various time points. Plasmids were
found in the spleen, liver, heart, lung, kidney, brain, and
diaphragm 1 h after administration (Figure 1). Notably,
plasmid distribution to the brain was comparable to that
to the other organs. Plasmid DNA was still present in all
organ samples 6 h post-dose, but the level of plasmids in
the brain was significantly lower than in other organs at
this time point. Plasmid DNA was detected only in the
spleen, kidney, and diaphragm 24 h after inoculation.
These results show that the arginine/DNA complexes
had diffused throughout the peritoneal cavity, and that
the plasmid DNA was delivered to various organs.
Quantification of mRNA expression in organs
To determine whether the plasmid DNA detected in var-
ious organs remained sufficiently intact for in vivo tran-
scription, the mRNA expression levels of luciferase DNA
in the organs were tested. Transgene expression was eval-
uated using the real time RT-PCR assay. The murine
housekeeping gene GAPDH was used as an internal con-
trol for the quantitative analysis. mRNA was detected in
all of the organs examined as early as 1 h after administra-
tion, with high levels of mRNA found in the spleen, liver,
and diaphragm, whereas the heart, lung, kidney, and brain
showed lower levels of gene expression (Figure 2). Expres-
sion levels peaked in the organs 3 h after administration of
plasmid DNA. The diaphragm showed the highest level of
mRNA expression and retained high levels of mRNA
expression until 24 h after administration. However, unlike
the diaphragm, the levels of mRNA expression in the
other organs decreased rapidly 12 h after administration.
These results indicate that the plasmid DNA delivered by
peptides to various organs remains sufficiently intact for
transcription.
pCMV-Luc plasmid DNA dose response
DNA dose effect on the level of mRNA expression was
also assessed using real time RT-PCR assay. Figure 3 illus-
trates data obtained when increasing amounts were
injected intraperitoneally into mice and the mRNA expres-
sion was determined 3 h later. In this experiment, 100,
200, and 300 μg of pCMV-Luc plasmid were complexed
with arginine peptide, so that the N/P ratio remained at
3:1. Interestingly, the expression level of target mRNA was
not increased in a plasmid DNA dose-dependent manner.
A significant level of mRNA expression was detected in all
organs, including the spleen, liver, lung, heart, brain, kid-
ney, and diaphragm, when 100 μg of pCMV-Luc plasmid
DNA was injected into mice. However, further increasing
the plasmid DNA dose to 300 μg did not result in a signifi-
cantly increased mRNA expression level in the organs.
Thus, the observed mRNA expression level appears to
saturate at a dose of 100 μgD N A / m o u s e .
Duration of plasmid DNA expression
Given the organ distribution and the optimum injection
volume results, we next examined the duration of plas-
mid DNA expression in various organs by nested PCR
analysis (Figure 4). Prolonged DNA expression was
observed in the spleen, kidney, and diaphragm. All
organs tested, except the brain, retained the expression
of the administered genes with a high level of mRNA
expression of luciferase relative to GAPDH in each
Figure 1 Organ distribution of plasmid DNA and the time
course of its clearance after delivery in arginine/DNA
complexes. Plasmid DNA (100 μg) complexed with arginine
peptide at an N/P ratio of 3:1 was intraperitoneally administered to
mice. The DNA was analyzed by PCR for the luciferase transgene
from various organs by using the specific primers described in the
Materials and Methods section. The PCR products were separated
on a 1.2% agarose gel.
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and diaphragm showed high levels of mRNA expression,
whereas the other organs did not show detectable levels
of mRNA expression 14 days after plasmid DNA appli-
cation. mRNA expression disappeared substantially in
all the tested organs 21 days after administration.
Blood clearance of plasmid DNA
To better understand the pharmacokinetic character of
plasmid DNA, its blood clearance profile was studied fol-
lowing intraperitoneal administration. The presence of
plasmid DNA was determined at select times by using
nested PCR analysis. A PCR band of plasmid DNA was
Figure 2 mRNA expression levels of the target gene in various organs. mRNA levels were evaluated using real time RT-PCR. Plasmid DNA
(100 μg) complexed with arginine peptide at an N/P ratio of 3:1 was intraperitoneally administered to mice. Mice were sacrificed at the
indicated time points, and total RNA was extracted from the organs. After preparation of cDNA, PCR amplification of luciferase and GAPDH
genes was performed using the specific primers described in the Materials and Methods section. Results are expressed as means ± S.D. for at
least 3 different experiments.
Figure 3 Effects of DNA dose on plasmid DNA expression after delivery in arginine/DNA complexes. Various amounts of plasmid DNA
complexed with arginine peptide at an N/P ratio of 3:1 were intraperitoneally administered to mice, and mRNA levels were evaluated using real
time RT-PCR. Total RNA was extracted from the organs. After preparation of cDNA, PCR amplification of luciferase and GAPDH genes was
performed using the specific primers described in the Materials and Methods section. Results are expressed as means ± S.D. for at least 3
different experiments.
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progressively later time points. Plasmid DNA was
detected up to 6 h post administration, whereas lower
levels of plasmid DNA were detected in the 12 h blood
sample and plasmid DNA was not detected after 12 h
(Figure 5). These results indicate that plasmid DNA is
stable for at least 6 h in the blood and can circulate in
the bloodstream, thereby increasing the opportunity for
delivery to target organs.
Discussion
CPPs have shown efficient in vitro transfection efficiency
without significant cellular toxicity [1]. Over the past
decade, peptide vectors have been shown to be an effec-
tive way of delivering DNA into cells, and unlike viral
vectors, peptides do not present safety concerns such as
immunogenicity and insertional mutagenesis. Peptide
vectors are able to compact and protect DNA, enter cells
via endocytosis, and deliver DNA cargo to the nucleus
[2,14]. Efficient cell-specific delivery of peptide/DNA
complexes is a major advantage of peptide vectors. Sev-
eral small peptides have been described, most notably the
tripeptide motif RGD, which targets integrin receptors
specially. RGD-containing peptides associated with
polylysine significantly improve the delivery of DNA into
specific cell lines [20]. Another targeting approach is to
use targeting moieties, such as the epidermal growth fac-
tor peptide which targets mainly cancer cells, covalently
linked to one of the component of the peptide/DNA
complex [21]. Although peptide vectors are under inten-
sive investigation as promising vectors for gene therapy,
relatively little information is available regarding the
Figure 4 Duration of plasmid DNA expression.P l a s m i dD N A( 1 0 0μg) complexed with arginine peptide at an N/P ratio of 3:1 was
intraperitoneally administered to mice, and total RNA was extracted from the organs at the indicated time points. The RNA extracts were
transformed to cDNA using RT-PCR to serve as templates for nested PCR analysis. PCR amplification of luciferase and GAPDH genes was
performed using the specific primers described in the Materials and Methods section. The nested PCR products were separated on a 1.2%
agarose gel.
Figure 5 Blood clearance of plasmid DNA after delivery in
arginine/DNA complexes. Plasmid DNA (100 μg) complexed with
arginine peptide at an N/P ratio of 3:1 was intraperitoneally
administered to mice. DNA was extracted from blood at the
indicated time points and used for nested PCR products. The nested
PCR products were separated on a 1.2% agarose gel.
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vectors. In this paper, the performance of a short arginine
p e p t i d e( R 1 5 )v e c t o ra sag e n ec a r r i e rw a se v a l u a t e din
vivo.
The biodistribution of DNA complexes with arginine
peptide after intraperitoneal administration was initially
investigated using PCR analysis, indicating that intraperi-
toneally applied arginine/DNA complexes were absorbed
into the systemic circulation and distributed to the major
organs of mice. Plasmid DNA was found in all analyzed
organs, including the spleen, liver, heart, lung, kidney,
brain, and diaphragm. Similar observations have been pre-
viously reported by other groups after intraperitoneal
injection of polyplex [22] or lipoplex in mice [23,24]. For
example, Louis et al. reported that large amounts of plas-
mid DNA were detected in the kidney, spleen, and dia-
phragm after intraperitoneal injection of DNA with
polyethylenimine [25]. It is notable that low but significant
quantities of plasmid DNA were localized in the brain.
Recently, it was reported that arginine peptide efficiently
facilitates rabies virus glycoprotein (RVG)-mediated brain
cell uptake of siRNA [11], and that high brain uptake
values were observed for penetratin and Tat [26]. These
results suggest that arginine-associated delivery will be
useful for the brain-directed transport of therapeutic
molecules. Plasmid DNA clearance varied in different
organs and the rapid disappearance of DNA from the
liver, heart, brain, and lungs suggests that plasmid DNA is
locally degraded by nucleases.
The mRNA expression pattern was in good agreement
with the plasmid DNA localization data. Significant
mRNA expression of the luciferase gene in the plasmid
DNA was observed in all of the tested organs (Figure 2).
mRNA was detected as early as 1 h after DNA injection,
suggesting that the intraperitoneally administered plasmid
DNA complexed with arginine peptide was delivered to
various organs in a sufficiently intact form for transcrip-
tion. Similar rapid gene expression was reported in a pre-
vious study, in which luciferase activity was detected as
early as 3 h after plasmid DNA infusion into mice [27]. In
agreement with the pattern of plasmid clearance revealed
by PCR analysis, the mRNA expression level was highest
in the spleen and diaphragm, in which the longest pre-
sence of plasmid DNA was observed. To determine the
effect of plasmid dose on mRNA expression, the plasmid
DNA dose was increased up to 300 μg. Interestingly, the
mRNA expression levels of plasmid DNA did not increase
with the increased amounts of plasmid DNA (Figure 3),
suggesting that a saturation phenomenon occurred under
these experimental conditions. Previous studies have
demonstrated that the gene expression level does not cor-
respond with the amount of administered cationic lipo-
some/DNA complexes [28,29].
Prolonged expression of plasmid DNA was observed in
arginine/DNA complex-treated mice (Figure 4), which is
comparable to the previous observations in naked DNA-
treated mice. However, the organs of naked DNA-treated
mice did not express mRNA from the topically or intra-
venously administered genes 3 to 5 days after dosing
[30]. In contrast, the results presented herein show that
some organs retained high levels of mRNA expression
for more than 14 days after application. Prolonged blood
circulation of plasmid DNA was also observed in argi-
nine/DNA complex-treated mice (Figure 5), and the
blood circulation time in the present study was 6 h. To
put this rate in context with other non-viral vectors,
polylysine/DNA complexes are cleared from circulation
within 5 to 30 min [31,32]. Cationic liposome/DNA com-
plexes are cleared more rapidly, with only 10% of the
injected complexes remaining detectable in the blood as
little as 1 min after injection [33]. Taken together, these
results provide evidence that arginine/DNA complexes
a r es t a b l ef o rar e l a t i v e l yp r o l o n g e dt i m eu n d e rin vivo
conditions, which is one of the critical requirements for
an efficient gene delivery vector. Furthermore, preferen-
tial plasmid distribution was observed in the diaphragm,
which presents a peritoneal surface. Tumors in the peri-
toneal cavity are difficult to detect and cancer often per-
sists despite surgery and other treatments [34]. In case of
ovarian cancer, overall 5-year survival rate is very low,
mainly as a consequence of late tumor detection (after
peritoneal dissemination) and chemoresistance following
chemotherapy. Therefore, the efficient peritoneal cavity-
preferential gene delivery and prolongation of complex
stability under in vivo conditions suggest that the intra-
peritoneal injection of arginine peptide/DNA complexes
will play an important role in future gene therapies for
peritoneal malignancies.
Conclusions
In summary, the present findings demonstrate that argi-
nine/DNA complexes are very stable when administered
intraperitoneally, and are effective agents for in vivo
gene delivery. Although optimization studies of these
strategies need to be continued, the information pre-
sented in this paper will be valuable for the development
of peptide-based vectors to enhance the potential of
gene therapy. Further studies will be focused on under-
standing the factors affecting the biodistribution and
examining the possibility of targeting specific organs
and cell types.
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